CFO Peter Pfreundschuh to depart Frequency Therapeutics March 31, 2022; no successor named

Korro Bio, Inc.

CFO Peter P. Pfreundschuh stepping down effective March 31, 2022; not due to any disagreement with the Company.
Severance includes 12 months base salary, $189,000 bonus, $20,000 relocation, and COBRA premium payments.
As of separation, 74,790 stock options are vested and exercisable; 330,210 shares remain unvested.
No replacement CFO has been announced; CEO David Lucchino signed the separation agreement.
Separation agreement includes standard release of claims, confidentiality, and non-disparagement clauses.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Peter P. Pfreundschuh

Chief Financial Officer

KRRO · Korro Bio, Inc.

Effective: 2022-03-31
Filed: March 31, 2022, 7:59 PM ET

On March 25, 2022, Peter P. Pfreundschuh notified Frequency Therapeutics, Inc. (the “Company”) that he was stepping down as Chief Financial Officer of the Company, effective March 31, 2022.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Peter P. Pfreundschuh departed as Chief Financial Officer at Korro Bio, Inc..

Action: stepped down
Role: Chief Financial Officer

Exact text from the filing

On March 25, 2022, Peter P. Pfreundschuh notified Frequency Therapeutics, Inc. (the “Company”) that he was stepping down as Chief Financial Officer of the Company, effective March 31, 2022.

View on SEC.gov

Korro Bio, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-22-092065

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.